Sotagliflozin
Sotagliflozin is a pharmaceutical drug with 28 clinical trials. Currently 8 active trials ongoing. Historical success rate of 77.8%.
Success Metrics
Based on 14 completed trials
Phase Distribution
Phase Distribution
5
Early Stage
6
Mid Stage
16
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
77.8%
14 of 18 finished
22.2%
4 ended early
8
trials recruiting
28
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
Clinical Trials (28)
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
Simultaneous Starting of the 4 Guideline Directed CKD Therapies (RAPID-CKD)
Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression
Sotagliflozin in Patients With Heart Failure Symptoms and Type 1 Diabetes
Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
A Study to Evaluate Safety and Effects of Sotagliflozin 400 and 200 mg on Glucose Control in Participants With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control
Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control
Efficacy and Bone Safety of Sotagliflozin 400 and 200 mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents
Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Participants With Worsening Heart Failure
Dose-ranging Study in Patients With Type 1 Diabetes Mellitus
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 28